Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C.

Journal of hepatology - 1 Aug 2003

Ahlenstiel Golo, Berg Thomas, Woitas Rainer P, Grünhage Frank, Iwan Agathe, Hess Lothar, Brackmann Hans H, Kupfer Bernd, Schernick Andrea, Sauerbruch Tilman, Spengler Ulrich

Abstract excerpt

BACKGROUND/AIMS: The CC-chemokine receptor (CCR) 5-Delta32 mutation may predispose to chronic liver disease and high level viremia in hepatitis C. However, it is unclear whether CCR5-Delta32 also affects the response to antiviral treatment. METHODS: We determined CCR5 genotypes in patients with hepatitis C treated with either interferon-alpha (N=78) or interferon and ribavirin (N=78). In each group, rates of end...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferons

Share to Multivariate Analysis

Share to Point Mutation

Share to Receptors, CCR5

Share to Ribavirin

Source

Identifiers

PMID: 12873822
DOI: 10.1016/s0168-8278(03)00193-4

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of the CCR5-Delta32 mutation on antiviral treatment in chronic hepatitis C.PMID 12873822Read ↗

Clinical significance of the CCR5delta32 allele in hepatitis C.Semantic proximity Read ↗

Frequency of the HIV-protective CC chemokine receptor 5-Delta32/Delta32 genotype is increased in hepatitis C.Semantic proximity Read ↗

CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection.Semantic proximity Read ↗

CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.Semantic proximity Read ↗

Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.Semantic proximity Read ↗

CCR5Δ32 in HCV infection, HCV/HIV co-infection, and HCV-related diseases.Semantic proximity Read ↗

The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source.Semantic proximity Read ↗

Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?Semantic proximity Read ↗

Effects of the CCR5-Delta32 mutation on hepatitis C virus-specific immune responses in patients with haemophilia.Semantic proximity Read ↗

Lack of higher frequency of the chemokine receptor 5-delta32/delta32 genotype in hepatitis C.Semantic proximity Read ↗

The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection.Semantic proximity Read ↗

The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.